abrdn plc Raises Holdings in ABIVAX Société Anonyme (NASDAQ:ABVX)

abrdn plc boosted its holdings in shares of ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) by 34.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 424,181 shares of the company's stock after buying an additional 107,750 shares during the period. abrdn plc owned approximately 0.67% of ABIVAX Société Anonyme worth $3,105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at about $36,000. GAMMA Investing LLC acquired a new position in ABIVAX Société Anonyme during the 4th quarter valued at approximately $29,000. Point72 Asset Management L.P. raised its holdings in shares of ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock worth $6,254,000 after buying an additional 119,300 shares during the last quarter. Walleye Capital LLC raised its holdings in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after buying an additional 80,807 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after buying an additional 5,900 shares during the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

ABIVAX Société Anonyme Stock Up 5.4 %

ABVX stock traded up $0.37 during mid-day trading on Thursday, reaching $7.17. The company's stock had a trading volume of 82,102 shares, compared to its average volume of 153,966. The company's 50 day moving average is $6.90 and its two-hundred day moving average is $9.34. ABIVAX Société Anonyme has a fifty-two week low of $5.49 and a fifty-two week high of $17.02.

Analyst Ratings Changes

ABVX has been the subject of a number of research analyst reports. Citizens Jmp upgraded ABIVAX Société Anonyme to a "strong-buy" rating in a research note on Wednesday, December 4th. JMP Securities restated a "market outperform" rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, ABIVAX Société Anonyme currently has a consensus rating of "Buy" and a consensus price target of $38.67.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.